Annals of hepatology · 2025
Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kocheise Lorenz, Kempski Jan, Tang Yunhe, Balcar Lorenz, Berger Victoria, Tomczak Miriam, Gorgulho Joao, Masood Ramsha, Giehren Franziska, Schmidt Constantin, Sutter Jan P, Fruendt Thorben W, Pagani Francesca, Wulf Sophie, Kött Julian, Domanig Saskia, Giannou Anastasios, Bedke Tanja, Lücke Jöran, Zhang Tao, Zhang Siwen, Machicote Andres, Lohse Ansgar W, Alunni-Fabbroni Marianna, Ricke Jens, Khaled Najib Ben, Pinter Matthias, Scheiner Bernhard, Huber Samuel, von Felden Johann, Piseddu Ignazio, Schulze Kornelius
Аннотация
INTRODUCTION AND OBJECTIVES: Immunotherapy with atezolizumab/bevacizumab (atezo/bev) is an established first-line treatment for patients with non-resectable hepatocellular carcinoma (HCC). Despite notable successes, only a subset of patients shows treatment response, highlighting the need for biomarkers to identify those likely to benefit from this therapy.
MATERIALS AND METHODS: In this biomarker study, 143 patients with atezo/bev-treated HCC were enrolled across three European centers. Baseline cytokine levels were measured using a flow cytometric multiplex bead assay. Overall survival (OS) analysis, reported as hazard ratios (HR), was conducted in an unbiased manner, with patients divided into a discovery cohort (one center, 63 patients) and a validation cohort (two centers, 80 patients).
RESULTS: Our cohorts show typical baseline characteristics of Western HCC patients, with alcohol-related liver disease (35.0 %) and hepatitis C (21.7 %) as the main HCC etiologies. Elevated serum IL-6 (cut-off 18.22 pg/ml) was associated with poor OS in both the discovery (HR 2.6, 95 % CI 1.2-5.6, p = 0.013) and validation cohorts (HR 2.4, 95 % CI 1.3-4.4, p = 0.005). Multivariate analysis confirmed elevated IL-6 to be a significant prognostic biomarker of poor OS (HR 2.1, 95 % CI 1.1-3.9, p = 0.021) after adjusting for established risk factors.
CONCLUSIONS: We identify elevated serum IL-6 levels as prognostic biomarker in patients with advanced HCC in Western countries. Importantly, this association was independent of infection with viral hepatitis, thus extending the previously reported associations between IL-6 and treatment response in East Asian cohorts.
MATERIALS AND METHODS: In this biomarker study, 143 patients with atezo/bev-treated HCC were enrolled across three European centers. Baseline cytokine levels were measured using a flow cytometric multiplex bead assay. Overall survival (OS) analysis, reported as hazard ratios (HR), was conducted in an unbiased manner, with patients divided into a discovery cohort (one center, 63 patients) and a validation cohort (two centers, 80 patients).
RESULTS: Our cohorts show typical baseline characteristics of Western HCC patients, with alcohol-related liver disease (35.0 %) and hepatitis C (21.7 %) as the main HCC etiologies. Elevated serum IL-6 (cut-off 18.22 pg/ml) was associated with poor OS in both the discovery (HR 2.6, 95 % CI 1.2-5.6, p = 0.013) and validation cohorts (HR 2.4, 95 % CI 1.3-4.4, p = 0.005). Multivariate analysis confirmed elevated IL-6 to be a significant prognostic biomarker of poor OS (HR 2.1, 95 % CI 1.1-3.9, p = 0.021) after adjusting for established risk factors.
CONCLUSIONS: We identify elevated serum IL-6 levels as prognostic biomarker in patients with advanced HCC in Western countries. Importantly, this association was independent of infection with viral hepatitis, thus extending the previously reported associations between IL-6 and treatment response in East Asian cohorts.